<DOC>
	<DOCNO>NCT02844439</DOCNO>
	<brief_summary>This multicenter , Phase 2 study ass activity tesevatinib patient recurrent glioblastoma .</brief_summary>
	<brief_title>Study Tesevatinib Monotherapy Patients With Recurrent Glioblastoma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<criteria>1 . Willingness ability provide write informed consent comply study protocol judge investigator 2 . Age ≥ 18 year old 3 . Kamofsky performance status ≥70 % 4 . Stable decrease dose corticosteroid within 5 day prior study 5. enrollment . 5 . For woman postmenopausal ( i.e. , &lt; 12 month last menstruation ) surgically sterile ( absence ovary and/or uterus ) sexually active : agreement use adequate method contraception ( oral contraceptive , intrauterine contraceptive device , barrier method contraception conjunction spermicidal jelly ) treatment period least 6 month last dose study drug . 6 . For male patient sexually active partner premenopausal woman : agreement use barrier method contraception treatment period least 6 month last dose study drug . 7 . Histologically confirm glioblastoma . A local pathology report constitute adequate documentation histology study inclusion . Patients initial diagnosis lowergrade glioma eligible subsequent biopsy determine glioblastoma . 8 . First recurrence concurrent adjuvant chemoradiotherapy . Imaging confirmation first tumor progression regrowth define RANO criterion . A minimum 12 week must elapse completion radiotherapy study entry minimize potential MRI change relate radiation necrosis might misdiagnosed progression disease , unless new lesion outside radiation field unequivocal evidence viable tumor histopathological sampling . 9 . Prior treatment TMZ low grade glioma glioblastoma . 10 . No one prior line systemic treatment glioblastoma . Concurrent adjuvant TMZbased chemotherapy , include combination TMZ investigational agent , consider one line therapy . 11 . Prior therapy gamma knife focal highdose radiotherapy allow , patient must subsequent histologic documentation recurrence , unless recurrence new lesion outside irradiated field . 12 . Recovery toxic effect prior therapy , minimum time : 1 . ≥ 28 day elapse administration prior cytotoxic agent , except ≥ 14 day vincristine , ≥ 21 day procarbazine , ≥ 42 day nitrosureas 2 . ≥ 28 day elapse administration investigational agent 3 . ≥ 14 day elapse administration noncytotoxic agent ( e.g. , interferon , tamoxifen , thalidomide , cisretinoic acid ) 13 . Patients undergone recent surgery recurrent progressive tumor eligible provide : 1 . Surgery must confirm recurrence 2 . There must residual disease 3 . A minimum 28 day must elapse day surgery first dose study drug . For core needle biopsy , minimum 7 day must elapse prior study entry 14 . Availability formalinfixed paraffinembedded tumor tissue diagnostic glioblastoma . 1 . Concurrent therapeutic intervention ( include radiation therapy NovoTTF ) . 2 . Prior exposure EGFR inhibitor . 3 . Prior exposure bevacizumab VEGF VEGFreceptortargeted agent within 8 week study start . 4 . Prior treatment prolifeprospan 20 carmustine wafer . 5 . Prior intracerebral agent . 6 . Evidence recent hemorrhage baseline MRI brain . However , patient clinically asymptomatic presence hemosiderin , resolve hemorrhagic change relate surgery , presence punctuate hemorrhage tumor eligible . 7 . Need urgent palliative intervention primary disease ( e.g. , rapidly increase intracranial pressure , impend herniation , uncontrolled seizure ) . 8 . Hematology : ANC &lt; 1.5 x109/L ; Plt &lt; 100 x109/L Hgb &lt; 9.0 g/dL within 7 day prior enrollment . The use transfusion intervention achieve Hb ≥ 9 g/dL acceptable . 9 . T.Bili . ≥ 1.5 x ULN ( except patient diagnose Gilbert 's disease ) . 10 . AST ( SGOT ) , ALT ( SGPT ) , alkaline phosphatase ( ALP ) ≥ 2.5 x ULN . 11 . S. Creat . &gt; 1.5 x ULN . 12 . K+ Mg+ &lt; LLN . 13 . In absence therapeutic intent anticoagulate patient : INR &gt; 1.5 PT &gt; 1.5 xULN aPTT &gt; 1.5 xULN Therapeutic anticoagulation . 14 . Known contraindication MRI , cardiac pacemaker , shrapnel ocular foreign body . 15 . Used prescription medication prior 2 week investigator judge likely interfere study pose additional risk patient participate , specifically inhibitor inducer cytochrome P450 ( CYP ) 3A4 ( refer Appendix 5 ) . A stable regimen ( ≥ 4 week ) antidepressant selective serotonin reuptake inhibitor ( SSRI ) class allow ( common SSRIs include escitalopram oxalate , citalopram , fluvoxamine , paroxetine , sertraline , fluoxetine ) . 16 . Taking drug associate torsades de pointes know moderately severely prolong QTc ( F ) interval 17 . History torsades de pointes , ventricular tachycardia fibrillation , pathologic sinus bradycardia ( &lt; 50 bpm ) , heart block ( exclude first degree block , PR interval ) , congenital long QT syndrome . Patients history atrial arrhythmia discuss Medical Monitor . 18 . Uncontrolled diabetes , evidence fast serum glucose level &gt; 200 mg/dL 19 . New York Heart Association ( NYHA ) Grade II great congestive cardiac failure . 20 . Has mark prolongation QTc ( F ) interval screen baseline ( QTc [ F ] interval &gt; 470 msec ) use Fridericia method correction heart rate . 21 . History myocardial infarction ( within 12 month ) unstable angina ( within 6 month ) prior study enrolment . 22 . History stroke transient ischemic attack within 6 month prior study enrolment . 23 . Significant vascular disease ( e.g. , aortic aneurysm require surgical repair recent peripheral arterial thrombosis ) within 6 month prior study enrolment . 24 . Evidence bleed diathesis coagulopathy ( absence therapeutic anticoagulation ) . 25 . History intracranial abscess within 6 month prior study enrolment . 26 . History another malignancy previous 3 year , diseasefree interval &lt; 3 year . Patients prior history situ cancer basal squamous cell skin cancer eligible . 27 . Evidence active infection require hospitalization IV antibiotic within 2 week prior study enrolment . 28 . Known hypersensitivity excipients tesevatinib . 29 . Inability swallow absorb orallyadministered medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>